C9orf72 and frontotemporal dementia: In this study, administration of a GA targeting antibody in a mouse model of C9orf72‐ALS/FTD, successfully attenuated neurodegeneration, improved behavioral outcomes, and increased survival (Nguyen et al, 2020).